Scar - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Scar - Pipeline Review, H1 2016', provides an overview of the Scar pipeline landscape. The report provides comprehensive information on the therapeutics under development for Scar, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Scar and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Scar - The report reviews pipeline therapeutics for Scar by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Scar therapeutics and enlists all their major and minor projects - The report assesses Scar therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Scar Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Scar - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Scar pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Scar Overview 9 Therapeutics Development 10 Pipeline Products for Scar - Overview 10 Pipeline Products for Scar - Comparative Analysis 11 Scar - Therapeutics under Development by Companies 12 Scar - Therapeutics under Investigation by Universities/Institutes 14 Scar - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Scar - Products under Development by Companies 18 Scar - Products under Investigation by Universities/Institutes 20 Scar - Companies Involved in Therapeutics Development 21 3M Drug Delivery Systems 21 AlbireoPharma 22 Altacor Limited 23 Beech Tree Labs, Inc. 24 Clanotech AB 25 EyeGene, Inc. 26 Fibrocell Science, Inc. 27 FirstString Research, Inc. 28 Isarna Therapeutics GmbH 29 Juventas Therapeutics, Inc. 30 LegoChem Biosciences, Inc 31 Moerae Matrix, Inc. 32 Pergamum AB 33 RXi Pharmaceuticals Corporation 34 VBS Pharmaceuticals 35 Scar - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Target 37 Assessment by Mechanism of Action 39 Assessment by Route of Administration 41 Assessment by Molecule Type 43 Drug Profiles 45 A-3914 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 A-5425 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 azficel-T - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 BTL-slo - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 CLT-28643 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 decorin - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Drug to Agonize Beta 2 Receptor for Wound Scars - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 EGS-001 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 EP-003 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 FS-2 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Granexin - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 ISTH-0036 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 JVS-100 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 LCB-030110 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 MG-53 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 MMI-0100 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 nefopam hydrochloride - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 OLX-101 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Polysaccharide for Wounds and Scars - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 PXL-01 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Recombinant Protein for Scar - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 RXI-109 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 S-34240 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 tranilast - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Scar - Recent Pipeline Updates 78 Scar - Dormant Projects 93 Scar - Discontinued Products 94 Scar - Product Development Milestones 95 Featured News & Press Releases 95 Feb 16, 2016: Accel-Rx/BDC make second portfolio investment in ScarX Therapeutics 95 Oct 12, 2015: RXi Pharmaceuticals to Present at Premier Scientific Plastic Surgery Meeting 96 Oct 05, 2015: RXi Pharmaceuticals Bolsters Protection for its Novel Self-Delivering RNAi Platform with Notice of Allowance from USPTO 96 Sep 29, 2015: RXi Pharmaceuticals to Present at Dawson James Securities Growth Stock Conference 97 Sep 28, 2015: RXi Pharmaceuticals Granted Patent in China for Lead Clinical Candidate RXI-109 97 Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 98 Mar 23, 2015: RXi Pharmaceuticals Reports Positive Advancements in its Dermatology Programs at the Occasion of the 73rd Annual Meeting of the American Academy of Dermatology 98 Dec 17, 2014: RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 99 Sep 29, 2014: RXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum 101 Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders 101 Appendix 102 Methodology 102 Coverage 102 Secondary Research 102 Primary Research 102 Expert Panel Validation 102 Contact Us 102 Disclaimer 103
List of Tables
Number of Products under Development for Scar, H1 2016 10 Number of Products under Development for Scar - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Development by Companies, H1 2016 (Contd..1) 19 Products under Investigation by Universities/Institutes, H1 2016 20 Scar - Pipeline by 3M Drug Delivery Systems, H1 2016 21 Scar - Pipeline by AlbireoPharma, H1 2016 22 Scar - Pipeline by Altacor Limited, H1 2016 23 Scar - Pipeline by Beech Tree Labs, Inc., H1 2016 24 Scar - Pipeline by Clanotech AB, H1 2016 25 Scar - Pipeline by EyeGene, Inc., H1 2016 26 Scar - Pipeline by Fibrocell Science, Inc., H1 2016 27 Scar - Pipeline by FirstString Research, Inc., H1 2016 28 Scar - Pipeline by Isarna Therapeutics GmbH, H1 2016 29 Scar - Pipeline by Juventas Therapeutics, Inc., H1 2016 30 Scar - Pipeline by LegoChem Biosciences, Inc, H1 2016 31 Scar - Pipeline by Moerae Matrix, Inc., H1 2016 32 Scar - Pipeline by Pergamum AB, H1 2016 33 Scar - Pipeline by RXi Pharmaceuticals Corporation, H1 2016 34 Scar - Pipeline by VBS Pharmaceuticals, H1 2016 35 Assessment by Monotherapy Products, H1 2016 36 Number of Products by Stage and Target, H1 2016 38 Number of Products by Stage and Mechanism of Action, H1 2016 40 Number of Products by Stage and Route of Administration, H1 2016 42 Number of Products by Stage and Molecule Type, H1 2016 44 Scar Therapeutics - Recent Pipeline Updates, H1 2016 78 Scar - Dormant Projects, H1 2016 93 Scar - Discontinued Products, H1 2016 94
List of Figures
Number of Products under Development for Scar, H1 2016 10 Number of Products under Development for Scar - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Products, H1 2016 17 Assessment by Monotherapy Products, H1 2016 36 Number of Products by Top 10 Targets, H1 2016 37 Number of Products by Stage and Top 10 Targets, H1 2016 37 Number of Products by Top 10 Mechanism of Actions, H1 2016 39 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 39 Number of Products by Routes of Administration, H1 2016 41 Number of Products by Stage and Routes of Administration, H1 2016 41 Number of Products by Molecule Types, H1 2016 43 Number of Products by Stage and Molecule Types, H1 2016 43
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Global outsourced customer care services market is projected to reach USD 84.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Swelling need for interaction through non-voice channels is estimated to boost global demand over tRead More...
Global Bio polyethylene terephthalate (PET) market size is likely to be valued at USD 12.6 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing preference of biopolymers in numerous applications coupled with favorable goverRead More...
Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the markeRead More...
Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. IncreasinRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.